Literature DB >> 9801263

Hematopoietic stem cell transplantation for primary lymphoid immunodeficiencies.

N Kapoor1, G Crooks, D B Kohn, R Parkman.   

Abstract

Hematopoietic stem cell (HSC) transplantation is curative therapy for many primary immunodeficiencies. All forms of severe combined immune deficiency (SCID) can be cured, but the extent of the immunologic correction is dependent on the pathophysiology of the primary defect. Defects involving lymphocyte differentiation are more easily corrected than defects in lymphocyte function because a selective advantage exists for the progeny of the normal donor HSC when the primary defect affects lymphocyte differentiation. T-cell-depleted (TCD), haploidentical-HSC transplantation can cure many forms of SCID, but not other primary immunodeficiencies like the Wiskott-Aldrich syndrome (WAS). Unrelated bone marrow and umbilical cord blood are alternative sources of HSC for patients who do not have histocompatible donors.

Entities:  

Mesh:

Year:  1998        PMID: 9801263

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  3 in total

Review 1.  Thymopoiesis and T cell development in common gamma chain-deficient dogs.

Authors:  Peter J Felsburg; Brian J Hartnett; Terry A Gouthro; Paula S Henthorn
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

2.  T cell repertoire development in XSCID dogs following nonconditioned allogeneic bone marrow transplantation.

Authors:  William Vernau; Brian J Hartnett; Douglas R Kennedy; Peter F Moore; Paula S Henthorn; Kenneth I Weinberg; Peter J Felsburg
Journal:  Biol Blood Marrow Transplant       Date:  2007-08-02       Impact factor: 5.742

3.  Musings on genome medicine: enzyme-replacement therapy of the lysosomal storage diseases.

Authors:  David G Nathan; Stuart H Orkin
Journal:  Genome Med       Date:  2009-12-09       Impact factor: 11.117

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.